Stephen Adams
Family Medicine · Springfield, MONPI 1245363993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $496,311 of the $636,342 with a category attached, or 78.0%. Viiv Healthcare Company accounts for 84.8% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $153,050 and has fallen 61.1% since, to $59,503 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,366 payments — averaging $465.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$539K
- Gilead$89K
- AbbVie$956
- Merck$939
- Johnson & Johnson$926
- Otsuka America Pharmaceutical, Inc.$813
- plus $4K from 27 others
What the payments were for
- Consulting fees$14,5802%
- Speaking & faculty fees$496,31178%
- Travel & lodging$96,62115%
- Food & beverage$28,3604%
- Education$4700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 651 | $539,394 |
| Gilead | 313 | $89,128 |
| AbbVie(2 entities) | 44 | $956 |
| Merck | 50 | $939 |
| Johnson & Johnson(2 entities) | 66 | $926 |
| Otsuka America Pharmaceutical, Inc. | 41 | $813 |
| Neurocrine Biosciences, Inc. | 20 | $463 |
| Napo Pharmaceuticals Inc | 24 | $442 |
| EMD Serono, Inc. | 22 | $414 |
| Vanda Pharmaceuticals Inc. | 16 | $406 |
| Janssen Products, LP | 4 | $398 |
| Teva Pharmaceuticals USA, Inc. | 16 | $227 |
| Lundbeck LLC | 13 | $223 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $212 |
| Amgen | 12 | $211 |
| Novo Nordisk | 4 | $174 |
| Antares Pharma, Inc. | 11 | $156 |
| Alkermes, Inc. | 8 | $151 |
| Supernus Pharmaceuticals, Inc. | 8 | $113 |
| Lilly USA, LLC | 5 | $92 |
| Janssen Scientific Affairs, LLC | 1 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $80 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| GSK | 1 | $51 |
| VBI Vaccine (delaware) Inc. | 3 | $44 |
| Pfizer | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Boehringer Ingelheim | 2 | $23 |
| Mylan Institutional Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Halozyme Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$636,342 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 376 | $1,497,165 |
| DovatoDolutegravir Sodium/Lamivudine | 222 | $689,281 |
| SerostimSomatropin | 23 | $474,143 |
| CabenuvaCabotegravir/Rilpivirine | 66 | $436,475 |
| TivicayDolutegravir Sodium | 161 | $426,698 |
| DescovyEmtricitabine/Tenofov Alafenam | 74 | $158,464 |
| MytesiCrofelemer | 47 | $116,463 |
| PifeltroDoravirine | 55 | $93,910 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $56,309 |
| PrezcobixDarunavir/Cobicistat | 23 | $56,137 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,779 |
| OzempicSemaglutide | 35 | $33,735 |
| Isentress HdRaltegravir Potassium | 12 | $23,575 |
| MounjaroTirzepatide | 17 | $18,331 |
| JardianceEmpagliflozin | 19 | $15,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $89,128 | $1,711,938464 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay | $539,394 | $1,552,454449 claims |
| EMD Serono, Inc.Serostim | $414 | $474,14323 claims |
| MerckPifeltro, Isentress Hd | $939 | $117,48567 claims |
| Napo Pharmaceuticals IncMytesi | $442 | $116,46347 claims |
| Johnson & JohnsonPrezcobix | $926 | $56,13723 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $23 | $40,48667 claims |
| Novo NordiskOzempic | $174 | $33,73535 claims |
| Lilly USA, LLCMounjaro | $92 | $18,33117 claims |
| GSKIncruse Ellipta, Arexvy | $51 | $9,05129 claims |
| PfizerEliquis | $31 | $8,46115 claims |
| AstraZenecaSymbicort | $27 | $2,73212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Springfield
- Roger CadySpringfield$175K
- Don BrockmanSpringfield$31K
- James van RiessenSpringfield$25K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.